Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by ...

Novo Nordisk on Monday announced a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the ...

Novo Nordisk and United Laboratories International’s subsidiary, United Biotechnology Co. have entered into a potentially $2 ...

Novo Nordisk NVO shares have lost 15.2% so far this month compared with the industry’s decline of 4.6%. The company has also ...

Drugmaker Novo Nordisk A/S (NVO) on Monday entered into an exclusive license agreement worth up to $2 billion with ...

Co., Ltd. have entered into an exclusive license agreement for UBT251 for the treatment of obesity, type 2 diabetes, and other diseases.

Novo will license UTB251, a triple hormone receptor agonist that in mid-2023 achieved promising weight reduction in a ...

Guangdong, China and Bagsværd, Denmark, 24 March 2025 –The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (Novo Nordisk) today announced that Novo Nordisk and TUL’s ...

Reuters reports that the FDA has approved Novo Nordisk (CO:NOVOb)'s (NVO -0.2%) fast-acting insulin aspart, branded as Fiasp.... Investing.com – Denmark stocks were higher after the close on ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

ByInvesting.com • Oct 20, 2021 Cigna's pharmacy benefit unit to prefer cheaper insulin drug from Viatris (Reuters) - Cigna Corp (NYSE:CI)'s pharmacy benefit unit said on Wednesday it will prefer ...

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better. Bagsværd, Denmark-based Novo Nordisk is a global healthcare company and a prominent player in the diabetes ...